These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25248846)

  • 1. Pharmacokinetics of antidepressants in patients with hepatic impairment.
    Mauri MC; Fiorentini A; Paletta S; Altamura AC
    Clin Pharmacokinet; 2014 Dec; 53(12):1069-81. PubMed ID: 25248846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.
    Schlatter C; Egger SS; Tchambaz L; Krähenbühl S
    Drug Saf; 2009; 32(7):561-78. PubMed ID: 19530743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
    Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of antidepressant pharmacokinetics and pharmacogenetics.
    Cohen LJ; De Vane CL
    Ann Pharmacother; 1996 Dec; 30(12):1471-80. PubMed ID: 8968460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of liver disease on pharmacokinetics. An update.
    Rodighiero V
    Clin Pharmacokinet; 1999 Nov; 37(5):399-431. PubMed ID: 10589374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).
    Nagler EV; Webster AC; Vanholder R; Zoccali C
    Nephrol Dial Transplant; 2012 Oct; 27(10):3736-45. PubMed ID: 22859791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in pharmacokinetics of antidepressants.
    Kokras N; Dalla C; Papadopoulou-Daifoti Z
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):213-26. PubMed ID: 21192772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.
    Talal AH; Venuto CS; Younis I
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):206-212. PubMed ID: 28263464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
    de Zeeuw D; Remuzzi G; Kirch W
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment.
    Christopher RJ; Morgan ME; Tang Y; Anderson C; Sanchez M; Shanahan W
    Clin Ther; 2017 Apr; 39(4):837-848.e7. PubMed ID: 28365033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antidepressant and antimanic drugs--pharmacological mechanisms and pharmacokinetics].
    Kiuchi Y; Oguchi E; Oguchi K
    Nihon Rinsho; 1994 May; 52(5):1190-5. PubMed ID: 8007387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants -- an update.
    Tanaka E; Misawa S
    J Clin Pharm Ther; 1998 Oct; 23(5):331-6. PubMed ID: 9875680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the newer antidepressants: clinical relevance.
    DeVane CL
    Am J Med; 1994 Dec; 97(6A):13S-23S. PubMed ID: 7992822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analgesics in patients with hepatic impairment: pharmacology and clinical implications.
    Bosilkovska M; Walder B; Besson M; Daali Y; Desmeules J
    Drugs; 2012 Aug; 72(12):1645-69. PubMed ID: 22867045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
    Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor.
    Dostert P; Benedetti MS; Poggesi I
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S23-35; discussion S71-3. PubMed ID: 9169308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.